FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	DC	20549
vvasiiiiiqtoii,	D.C.	20049

STATEMENT OF CHANGES IN BENEFICIAL	OWNERSHIP
------------------------------------	-----------

OMB APPROVAL								
ОМВ	Number:	3235-0287						
Estimated average burden								
hours	ner resnonse	. 0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Jorgensen Nathan D.				2. Issuer Name and Ticker or Trading Symbol Voyager Therapeutics, Inc. [VYGR]						Relationship of Reporting Person(s) to Issuer (Check all applicable) Director						
(Last)	,	First)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 07/08/2024					V	below) "	give title		Other (specify below) Officer		
75 HAYDEN AVENUE					4. If Amendment, Date of Original Filed (Month/Day/Year)					Line)	1 <u>-</u>					
(Street)	TON M	1A	02421							V	Form filed by One Reporting Person Form filed by More than One Reporting Person				ng	
(City)	(S	State)	(Zip)		Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.											
					ative Securities Acquired, Disposed of, or Benefic									. Nature of		
Date			ate	Execution Date, if any (Month/Day/Year)		Date,	Transaction Disposed Of (D) (Instr. 3, 4)						Form: y (D) or	Direct Indirect Bestr. 4)	ndirect eneficial wnership nstr. 4)	
							Code V	Amount	(A) or (D)	Price	Transaction (Instr. 3 and				11501. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security		ercise of ative (Month/Day/Year)	Execution Date, if any	4. Transa Code (5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)			
Stock Option (Right to Buy)	\$7.79	07/08/2024		A		200,000 ⁽¹⁾		(2)	07/08/2034	Common Stock	200,000	\$0	200,00	00	D	

Explanation of Responses:

- 1. This stock option was not granted pursuant to any pre-existing equity incentive plan of Voyager Therapeutics, Inc. (the "Company"), but rather was granted as an inducement material to the Reporting Person entering into employment with the Company in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4).
- 2. The vesting commencement date of the option is the grant date. The option vests over four years, with 1/4th of the shares of common stock underlying the option vesting upon the one-year anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service as an employee.

/s/ Scott MacDonald, as Attorney-in-Fact for Nathan D. 07/09/2024

<u>Jorgensen</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.